Clinical Overview of 5-Amino-1MQ

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Mechanism of Action

5-amino-1MQ is a small-molecule compound that acts as an inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). NNMT is a cytosolic enzyme that transfers a methyl group from the cofactor S-adenosyl-L-methionine (SAM) to substrates such as nicotinamide, pyridines, and their analogues. Through this activity, NNMT regulates the detoxification of both endogenous metabolites and xenobiotics, producing compounds such as 1-methylnicotinamide (1-MNA) and other methylated derivatives.

Although the liver contains the highest levels of NNMT, the enzyme is also present in adipose tissue, kidney, brain, lung, heart, and skeletal muscle. Elevated NNMT expression and activity have been linked to several chronic pathologies, making it a significant therapeutic target. Increased NNMT expression has been observed in multiple cancer types, where it contributes to tumor cell proliferation and disease progression. Similarly, upregulation of NNMT has been associated with neurodegenerative conditions such as Parkinson’s disease, where NNMT activity may facilitate the production of neurotoxic compounds including N-methylpyridinium ions.

Role in Metabolic Regulation and Weight Management

NNMT has been implicated in obesity, type 2 diabetes, cardiovascular disease, renal dysfunction, and metabolic syndrome. Elevated levels of NNMT and its metabolite 1-MNA correlate with excess adiposity and impaired glucose metabolism.

Experimental studies demonstrate that pharmacological inhibition of NNMT reduces white adipose tissue mass, decreases lipogenesis, and enhances overall energy expenditure. In animal models of diet-induced obesity, NNMT inhibitors lowered adipocyte size and volume, reduced circulating cholesterol levels by approximately 30%, and suppressed lipogenesis by up to 70% in treated adipocytes. Importantly, these effects occurred without changes in food intake and were achieved with minimal toxicity.

Mechanistically, NNMT inhibition appears to increase intracellular pools of NAD+ and SAM in adipocytes, thereby promoting pathways of energy metabolism and lipid turnover. This highlights the therapeutic potential of NNMT inhibitors in managing obesity and its associated comorbidities.

Effects on Skeletal Muscle Regeneration

Skeletal muscle regeneration relies on the activation of satellite cells (muscle stem cells, or MuSCs). Aging is associated with impaired MuSC proliferation and differentiation, leading to reduced muscle repair after injury. Pharmacological NNMT inhibition has been investigated as a strategy to restore MuSC function in aged muscle.

In animal studies, treatment with NNMT inhibitors enhanced MuSC proliferation and fusion, resulting in larger myofiber cross-sectional areas and improved contractile function following injury. Peak torque generation of regenerating muscle increased by approximately 70% in treated animals compared to controls. These findings suggest NNMT inhibition may represent a novel therapeutic avenue for improving recovery from musculoskeletal injury and mitigating age-related declines in regenerative capacity.

Implications for Age-Related Muscle Loss

Sarcopenia, defined as progressive loss of muscle mass and function with aging, is linked to chronic inflammation and mitochondrial dysfunction. Research indicates that impaired clearance of damaged mitochondria contributes to inflammatory cascades that exacerbate muscle atrophy. The protein BNIP3, which regulates mitochondrial turnover, has been identified as a protective factor against age-related muscle deterioration.

NNMT inhibition has been shown to promote muscle regeneration, enhance neuromuscular function, and reduce atrophy by restoring satellite cell activity and improving cellular energy metabolism. These properties highlight the potential of 5-amino-1MQ and related NNMT inhibitors as therapeutic agents to combat sarcopenia and muscular degeneration associated with aging.

REFERENCES

1. Neelakantan, H., Brightwell, C. R., Graber, T. G., Maroto, R., Wang, H. L., McHardy, S. F., Papaconstantinou, J., Fry, C. S., & Watowich, S. J. (2019). Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical pharmacology, 163, 481–492. https://doi.org/10.1016/j.bcp.2019.02.008
2. Jang, Y. C., Sinha, M., Cerletti, M., Dall’Osso, C., & Wagers, A. J. (2011). Skeletal muscle stem cells: effects of aging and metabolism on muscle regenerative function. Cold Spring Harbor symposia on quantitative biology, 76, 101–111. https://doi.org/10.1101/sqb.2011.76.010652
3. Kannt, A., Rajagopal, S., Kadnur, S.V. et al. A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders. Sci Rep 8, 3660 (2018). https://doi.org/10.1038/s41598-018-22081-7

Product available for research use only: